Hepatitis E – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Hepatitis E virus (HEV), belonging to the family Hepeviridae, is a positive sense, single-stranded RNA virus with a genomic length ranging from 6.6 to 7.2 kilobases, containing three open reading frames (ORFs). ORF1, ORF2, ORF3 encodes. There are eight genotypes of HEV. HEV is mainly transmitted through the fecal-oral route, with genotypes 1 and 2 often spreading through contaminated water and leading to large outbreaks in developing regions. Genotypes 3 and 4 are dominant in developed regions, and HEV mainly transmits to humans through contaminated animal products, such as uncooked meat or liver. HEV infection usually results in self-limited acute hepatitis, with clinical manifestations such as anorexia, nausea, vomiting, malaise, abdominal pain, and jaundice lasting less than one month. The incubation period of hepatitis E ranges from 15 to 60 days, and HEV RNA can be detected in feces and serum samples from patients three weeks after infection.
- HEV infections are highly prevalent worldwide, with an estimated 20 million cases reported annually. These infections lead to approximately 3.3 million cases of symptomatic hepatitis E.
Thelansis’s “Hepatitis E Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hepatitis E treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Hepatitis E across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Hepatitis E Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment